


CellProtect

Nordic Pharmaceuticals AB




Karin Mellström, CEO

Multiple Myeloma

a treatable, but still incurable disease

First line treatment high dose chemotherapy followed by autologous stem cell transplant (only younger and fit patients)



Autologous SCT + drug treatment*	<65-70 YR
Drug treatment alone	>65-70 YR
Wait and see	Smoldering Myeloma


* = roughly 1/3 of patients

How can we complement the existing treatments and potentially achieve cure ?

Multiple Myeloma

CellProtect autologous NK cells

- Highly selective cytotoxicity against MM cells
- Indication of no *off target effects*
- 20 days of *ex vivo* activation optimal




CellProtect shows significant efficacy versus autologous MM cells without off target effects



CellProtect

The NK cell product

- Unique & patented cell-culturing and expansion of NK cell from the patients' own blood
- Manufacturing cost roughly 1/2 and 1/5 of allogeneic NK cell lines and CAR-T cells respectively
- Activation of at least 30% of expanded NK cells
- High cytotoxicity
- Finished material frozen with shelf life of at least 48 months (84 months ongoing)




Detailed phenotypic characterization of NK cell degranulation and cytotoxicity assays

A cell therapy product with competitive cost structure and favourable shelf life

Phase I/II clinical trial

- Aim was to investigate use of CellProtect as adjunct treatment to ASCT in MM patients
- Conducted a phase I/II clinical trial, first-in-man, 6 patients, therapeutic explorative study, primarily to investigate safety and tolerability



**Early clinical results;
a safe product with indications of efficacy**

Investment Case

- **Individualized cell therapy product**
 - Validated GMP manufacturing method of an *ex vivo* autologous, expanded and activated natural killer (NK) cell therapy product (CellProtect)
 - Phase I/II clinical trial in newly diagnosed Multiple Myeloma (MM) patients with promising results
- **Orphan drug designation EMA**
- **Patents** covering manufacturing process and treatment of MM; further new patent application is being planned for.
- **World-class team**
- SEK 65m/USD 8m investment sought to enable confirmatory clinical trials

An attractive investment opportunity in a potentially game-changing cell therapy company